ENDRA Life Sciences Inc. (NASDAQ:NDRA) CTO Michael Milos Thornton Sells 15,000 Shares of Stock


Share on StockTwits

ENDRA Life Sciences Inc. (NASDAQ:NDRA) CTO Michael Milos Thornton sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 7th. The stock was sold at an average price of $2.53, for a total value of $37,950.00. Following the sale, the chief technology officer now directly owns 274,960 shares of the company’s stock, valued at approximately $695,648.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Michael Milos Thornton also recently made the following trade(s):

  • On Monday, March 29th, Michael Milos Thornton sold 18,750 shares of ENDRA Life Sciences stock. The shares were sold at an average price of $2.37, for a total value of $44,437.50.

Shares of NDRA opened at $2.51 on Thursday. The firm has a market cap of $104.42 million, a PE ratio of -1.36 and a beta of 1.60. The stock’s fifty day moving average price is $2.49 and its two-hundred day moving average price is $1.42. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.42 and a quick ratio of 3.19. ENDRA Life Sciences Inc. has a 1 year low of $0.60 and a 1 year high of $3.10.

ENDRA Life Sciences (NASDAQ:NDRA) last issued its earnings results on Wednesday, March 24th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.04. Sell-side analysts anticipate that ENDRA Life Sciences Inc. will post -0.71 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. K.J. Harrison & Partners Inc raised its stake in shares of ENDRA Life Sciences by 60.9% during the 4th quarter. K.J. Harrison & Partners Inc now owns 277,629 shares of the company’s stock valued at $208,000 after purchasing an additional 105,129 shares during the period. Virtu Financial LLC raised its stake in shares of ENDRA Life Sciences by 62.5% during the 3rd quarter. Virtu Financial LLC now owns 41,738 shares of the company’s stock valued at $31,000 after purchasing an additional 16,057 shares during the period. HN Saltoro Capital LP bought a new stake in shares of ENDRA Life Sciences during the 4th quarter valued at $145,000. Worth Venture Partners LLC bought a new stake in shares of ENDRA Life Sciences during the 4th quarter valued at $247,000. Finally, Renaissance Technologies LLC bought a new stake in shares of ENDRA Life Sciences during the 4th quarter valued at $65,000. Institutional investors own 2.84% of the company’s stock.

Separately, Zacks Investment Research cut ENDRA Life Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 20th.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion.

Further Reading: How liquidity affects the bid-ask spread

Insider Buying and Selling by Quarter for ENDRA Life Sciences (NASDAQ:NDRA)

Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.